Ramsay Stattman Vela & Price Inc. Acquires 918 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Ramsay Stattman Vela & Price Inc. grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,211 shares of the medical research company's stock after purchasing an additional 918 shares during the period. Thermo Fisher Scientific comprises about 1.5% of Ramsay Stattman Vela & Price Inc.'s investment portfolio, making the stock its 24th biggest position. Ramsay Stattman Vela & Price Inc.'s holdings in Thermo Fisher Scientific were worth $8,067,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in TMO. Vanguard Group Inc. lifted its holdings in Thermo Fisher Scientific by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company's stock valued at $17,297,426,000 after purchasing an additional 196,864 shares during the last quarter. Capital World Investors grew its holdings in Thermo Fisher Scientific by 1.1% during the fourth quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock valued at $4,905,812,000 after purchasing an additional 104,343 shares during the period. Geode Capital Management LLC grew its holdings in Thermo Fisher Scientific by 2.6% during the fourth quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company's stock valued at $4,075,540,000 after purchasing an additional 197,442 shares during the period. Norges Bank bought a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $3,149,754,000. Finally, Northern Trust Corp lifted its stake in Thermo Fisher Scientific by 13.2% in the fourth quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock valued at $2,034,107,000 after buying an additional 455,004 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of research reports. UBS Group lowered shares of Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and cut their price target for the company from $500.00 to $460.00 in a research note on Tuesday. Stifel Nicolaus cut their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Royal Bank Of Canada reduced their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Finally, Robert W. Baird reduced their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus price target of $600.30.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president directly owned 23,167 shares in the company, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO traded up $4.29 during trading hours on Friday, hitting $435.02. The company had a trading volume of 2,511,384 shares, compared to its average volume of 1,999,630. The firm has a market cap of $164.22 billion, a price-to-earnings ratio of 25.51, a PEG ratio of 2.31 and a beta of 0.77. The business has a fifty day moving average of $409.39 and a 200-day moving average of $476.23. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The business had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same period in the prior year, the company posted $5.11 earnings per share. Thermo Fisher Scientific's revenue was up .2% compared to the same quarter last year. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. Thermo Fisher Scientific's payout ratio is currently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.